Press Releases
-
Aug 3, 2015
In First Six Months of 2015 Vimizim Sales Top $104 million and Total BioMarin Revenue Grows 32% Y/YFinancial Highlights ($ in millions, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2015 2014 % Change 2015 2014 % Change Total BioMarin Revenue $ 250.5 $...
-
Jul 27, 2015
SAN RAFAEL, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it will become a component of the NASDAQ-100 Index® (NASDAQ:NDX), the...
-
Jul 20, 2015ABRAZO Phase 2 Study Meets Protocol-Specified Criteria to Expand Enrollment
SAN RAFAEL, Calif., July 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced an update on the ABRAZO Phase 2 study of its poly ADP-ribose polymerase (PARP)...
-
Jul 15, 2015
SAN RAFAEL, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...
-
Jun 29, 2015FDA Grants Priority Review Status
SAN RAFAEL, Calif., June 29, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the submission...
-
Jun 25, 2015
SAN RAFAEL, Calif., June 25, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Medicines Agency (EMA) has validated the Marketing Authorization...
-
Jun 17, 201550% Increase in mean annualized growth velocity in 15 µg/kg/daily dose group
SAN RAFAEL, Calif., June 17, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111...
-
Jun 15, 2015
SAN RAFAEL, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that EY awarded BioMarin CEO Jean-Jacques Bienaimé the EY Entrepreneur Of The...
-
Jun 8, 2015
SAN RAFAEL, Calif., June 8, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the European...
-
Jun 4, 2015
SAN RAFAEL, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer at BioMarin, will present a...
-
May 1, 2015
SAN RAFAEL, Calif., May 1, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer at...
-
Apr 30, 2015Vimizim Sales Top $50 million in First Quarter of 2015 and $127 million in First Four Quarters Since Launch
Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended March 31, 2015 2014 % Change Total BioMarin Revenue $ 203.3 $ 151.5 34% Vimizim Net Product Revenue 50.6...
-
Apr 27, 2015
SAN RAFAEL, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced completion of the rolling submission of a New Drug Application (NDA) to the United...
-
Apr 23, 2015Interim analysis of prospective natural history increases understanding of Duchenne muscular dystrophy
SAN RAFAEL, Calif., April 23, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the results of a natural history study designed to prospectively evaluate the...
-
Apr 21, 2015
SAN RAFAEL, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on April 15, 2015, the compensation committee of BioMarin's board of...
-
Apr 14, 2015
SAN RAFAEL, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...
-
Mar 30, 2015Oral Presentation on Improvement in Attentiveness in Children and Adolescents With PKU Taking Kuvan(R) (sapropterin dihydrochloride), Based on Post Hoc Analysis
SAN RAFAEL, Calif., March 30, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the results of a post-hoc sub-analysis of the PKU-016 or ASCEND study, the largest...
-
Mar 18, 2015
SAN RAFAEL, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on March 16, 2015, the compensation committee of BioMarin's board of...
-
Feb 25, 2015Total BioMarin Revenue Increased 37% to $751 million in 2014
Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2014 2013 % Change 2014 2013 % Change Total BioMarin Revenue...
-
Feb 20, 2015
SAN RAFAEL, Calif., Feb. 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on February 17, 2015, the compensation committee of BioMarin's board of...
-
Feb 9, 2015
SAN RAFAEL, Calif., Feb. 9, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the company would make two data presenations in addition to presenting eight...
-
Feb 3, 2015
SAN RAFAEL, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...
-
Jan 30, 2015
SAN RAFAEL, Calif., Jan. 30, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the final results of, and the completion of the subsequent offering period relating...
-
Jan 23, 2015
SAN RAFAEL, Calif., Jan. 23, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the underwriters for its recently announced public offering of 8,500,000...
-
Jan 22, 2015
SAN RAFAEL, Calif., Jan. 22, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing of an underwritten public offering of 8,500,000 shares of its common...
-
Jan 21, 2015
SAN RAFAEL, Calif., Jan. 21, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 7,250,000 shares of its...
-
Jan 15, 2015
SAN RAFAEL, Calif., Jan. 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it completed the initial offering period for the previously announced tender...
-
Jan 12, 2015Preliminary Results Show Evidence of Disease Stabilization
SAN RAFAEL, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced interim results from its Phase 1/2 pivotal study for BMN 190 or cerliponase alfa, a...
-
Jan 7, 2015Jean-Jacques Bienaimé to Assume the Role of Chairman
SAN RAFAEL, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that, after a tenure of more than a decade, Pierre Lapalme has elected to step down...
-
Dec 29, 2014First and Only Treatment in Japan Approved for Patients With This Ultra-Rare Genetic Condition
SAN RAFAEL, Calif., Dec. 29, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Ministry of Health, Labor and Welfare granted approval of the registration of...
-
Dec 24, 2014
SAN RAFAEL, Calif., Dec. 24, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced the expiration of the mandatory waiting...
-
Dec 10, 2014Clinical Studies Expected to Begin in Mid-2015
SAN RAFAEL, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for...
-
Dec 10, 2014VIMIZIM is First and Only Treatment in Brazil for Patients With This Ultra-Rare Genetic Condition
SAN RAFAEL, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Agência Nacional de Vigilancia Sanitaria (ANVISA), or the National Health...
-
Dec 9, 2014Company to Profile Key Pipeline and Commercial Portfolio Assets
SAN RAFAEL, Calif., Dec. 9, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) will host an Analyst and Investor Day from 8am (ET) to 1pm (ET) on Wednesday, December 10, 2014 at...
-
Dec 7, 2014First and Only Treatment in Australia for Patients With This Ultra-Rare Genetic Condition
SAN RAFAEL, Calif., Dec. 7, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Australian Therapeutic Goods Administration (TGA) granted approval of the...
-
Dec 3, 2014
SAN RAFAEL, Calif., Dec. 3, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) will host an Analyst & Investor Day for the investment community on Wednesday, December 10, 2014...
-
Nov 24, 2014Acquisition of Prosensa provides near-term opportunity to commercialize, if approved, its exon-skipping drug candidate,drisapersen, for Duchenne muscular dystrophy (DMD)
SAN RAFAEL, Calif., Nov. 24, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced that they have entered into a definitive...
-
Nov 19, 2014Deutsche Bank BioFEST on December 2
SAN RAFAEL, Calif., Nov. 19, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today announced that management will participate in the Deutsche Bank BioFEST on December 2, 2014...
-
Oct 23, 2014VIMIZIM® Sales Top $25 million in Second Full Quarter of Sales
Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2014 2013 % Change 2014 2013 % Change Total BioMarin Revenue...
-
Sep 24, 2014
SAN RAFAEL, Calif., Sept. 24, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that a Paragraph IV Certification Notice Letter was submitted to the US Food and...
-
Sep 23, 2014Jefferies Gene Therapy Summit on September 30 in Boston
SAN RAFAEL, Calif., Sept. 23, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today announced that management will participate in the Jefferies Gene Therapy Summit on September 30
-
Sep 15, 2014Analysis Shows That BioMarin is a Leader in Speed and Efficiency of Bringing New Treatments to Patients
SAN RAFAEL, Calif., Sept. 15, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that CenterWatch, a leading source for global clinical trial information, has...
-
Jul 30, 2014
SAN RAFAEL, Calif., July 30, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has sold the Rare Pediatric Disease Priority Review Voucher (PRV) it...
-
Jul 30, 2014VIMIZIM® Sales Top $14 million in First Full Quarter of Sales
Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2014 2013 % Change 2014 2013 % Change Total BioMarin Revenue $ 191.7 $...
-
Jul 23, 2014Patient Enrollment Expands Internationally With First Patient Outside of U.S.
SAN RAFAEL, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Sarah Cannon Research Institute UK today announced a collaboration to enroll patients in an...
-
Jul 7, 2014Approval delivers first pharmaceutical therapy for children and adults with ultra-rare, life-limiting disorder
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that Health Canada has approved VIMIZIM™(elosulfase alfa) for long-term enzyme replacement therapy in patients with a confirmed...
-
May 27, 2014Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Improve Respiratory Muscle Strength in Patients With Rare Genetic Disorder
SAN RAFAEL, Calif., May 27, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient with BMN 701 (GILT-tagged Recombinant Human GAA)...
-
May 1, 2014Total BioMarin Revenue Grew 18.5% in 1Q14
Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended March 31, 2014 2013 % Change Total BioMarin Revenue $ 151.5 $ 127.9 18.5% Total BioMarin Revenue...
-
Apr 28, 2014VIMIZIM is the First and Only Specific Treatment for Patients With This Ultra-Rare Genetic Condition
SAN RAFAEL, Calif., April 28, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Commission has granted marketing authorization for VIMIZIM®...
-
Apr 14, 2014New Convenient Form of KUVAN Now Available for the Treatment of Phenylketonuria (PKU)
SAN RAFAEL, Calif., April 14, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases,...
-
Mar 22, 2014
SAN RAFAEL, Calif., March 21, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment...
-
Mar 5, 2014
SAN RAFAEL, Calif., March 5, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing on March 4, 2014 of an underwritten public offering of 1,500,000 shares...
-
Mar 4, 2014
SAN RAFAEL, Calif., March 4, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 1,500,000 shares of its...
-
Feb 26, 2014Total Revenue Grows 9.5% in 2013
Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2013 2012 % Change 2013 2012 % Change Total BioMarin Revenue...
-
Feb 20, 2014
SAN RAFAEL, Calif., Feb. 20, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European...
-
Feb 17, 2014Company to Host Conference Call and Webcast, Tuesday, February 18 at 8:00 a.m. ET
SAN RAFAEL, Calif., Feb. 17, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) will host a conference call and webcast on Tuesday, February 18, at 8:00 a.m. ET to discuss FDA...
-
Feb 14, 2014VIMIZIM is the First and Only Specific Treatment for Patients With This Ultra-Rare Genetic Condition
SAN RAFAEL, Calif., Feb. 14, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved VIMIZIM™...
-
Feb 13, 201412 Abstracts on MPS diseases and 3 on Pompe Disease
SAN RAFAEL, Calif., Feb. 13, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today 15 data presentations at the Lysosomal Disease Network's 10th Annual...
-
Feb 11, 2014Potential to Add Fourth MPS Treatment to BioMarin Franchise
SAN RAFAEL, Calif., Feb. 11, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has selected a new drug development candidate, BMN 250, a novel fusion of...
-
Jan 21, 2014Includes Compounds for Potential Treatment of Friedreich's Ataxia
SAN RAFAEL, Calif., Jan. 21, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has entered into an agreement to purchase Repligen Corporation's histone...
-
Jan 14, 2014
SAN RAFAEL, Calif., Jan. 14, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first child in the Phase 2 trial with BMN 111, an analog of...
-
Jan 13, 2014
SAN RAFAEL, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has selected an AAV-factor VIII vector, BMN 270, to develop for the...
-
Jan 13, 2014Recommend Drug Therapy, Such as Kuvan(R) (Sapropterin Dihydrochloride), for Appropriate Patients
SAN RAFAEL, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that new practice guidelines issued by the American College of Medical Genetics and...
-
Nov 19, 2013Advisory Committee of the Food and Drug Administration to Review BioMarin's Biologics License Application for Vimizim(TM) for the Treatment of Morquio A Syndrome
SAN RAFAEL, Calif., Nov. 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that NASDAQ has halted trading of the company's stock. The U.S. Food and Drug...
-
Nov 19, 2013
SAN RAFAEL, Calif., Nov. 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S....
-
Nov 15, 2013
SAN RAFAEL, Calif., Nov. 15, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the French National Agency for Medicines and Health Products Safety (ANSM) has...
-
Nov 15, 2013Endocrinologic and Metabolic Drugs Advisory Committee Meeting November 19, 2013
SAN RAFAEL, Calif., Nov. 15, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the U.S. Food and Drug Administration (FDA) posted briefing materials for the...
-
Oct 31, 2013
SAN RAFAEL, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient in its Phase 3 program to evaluate BMN 673, its...
-
Oct 24, 2013Total Revenue Grows 6.9% in the Quarter and 8.9% for First Three Quarters of 2013
Financial Highlights ($ in millions, except per share data, unaudited) Q3 2013 Q3 2012 Percent Change Total BioMarin Revenue $ 136.9 $ 128.1 6.9% Total BioMarin Revenue (excluding Aldurazyme Net...
-
Oct 20, 2013BMN 673 Potentially 100-Fold More Potent Than Other PARP Inhibitors
SAN RAFAEL, Calif., Oct. 20, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that five poster presentations on BMN 673 will be featured at the 2013...
-
Oct 10, 2013
SAN RAFAEL, Calif., Oct. 10, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced that the underwriters for its recently announced public offering of $680 million of its...
-
Oct 9, 2013
SAN RAFAEL, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced the pricing on October 8, 2013 of a total offering of $680 million of its senior...
-
Oct 7, 2013
SAN RAFAEL, Calif., Oct. 7, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of $600 million of its senior...
-
Sep 29, 2013Confirmed RECIST Response Rate of 50% in gBRCA Breast Cancer Patients Treated With 1mg/day Phase 3 Dose
SAN RAFAEL, Calif., Sept. 29, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced an update on the ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP)...
-
Sep 23, 2013
SAN RAFAEL, Calif., Sept. 23, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient in the Phase 1/2 trial for BMN 190, a...
-
Sep 17, 2013Vimizim: Regulatory applications on track. FDA Advisory Committee Meeting expected to be scheduled for November 19, 2013.
SAN RAFAEL, Calif., Sept. 17, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced highlights to be presented at the company's Research and Development Day for the...
-
Sep 3, 2013
SAN RAFAEL, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the appointment of Richard Ranieri as Senior Vice President, Human Resources and...
-
Aug 16, 2013Late Breaking Abstract on PARP Inhibition
SAN RAFAEL, Calif., Aug. 16, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that its abstract, PARP inhibition with BMN 673 in ovarian and breast cancer...
-
Jul 25, 2013Total Revenue Growth Exceeds 10 Percent
Financial Highlights ($ in millions, except per share data, unaudited) Q2 2013 Q2 2012 Percent Change Total BioMarin Revenue $ 136.8 $ 124.0 10.3% Total BioMarin Revenue (excluding Aldurazyme Net...
-
Jul 25, 2013RECIST Response Rate Increases to 50% in gBRCA Breast Cancer; Study Ongoing
SAN RAFAEL, Calif., July 25, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today provided an update on its ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP)...
-
Jul 1, 2013
SAN RAFAEL, Calif., July 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has submitted the Vimizim Marketing Application (MA) to the Agência...
-
Jun 6, 2013
SAN RAFAEL, Calif., June 6, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer at BioMarin, will present a...
-
Jun 5, 2013
SAN RAFAEL, Calif., June 5, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has initiated the Phase 3 program for PEG-PAL (PEGylated recombinant...
-
Jun 3, 2013Phase 3 Trial in Metastatic gBRCA Breast Cancer Planned to Start in Q4 2013
SAN RAFAEL, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced an update on the ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP)...
-
May 30, 2013Vimizim Designated for Accelerated Assessment by the EMA
SAN RAFAEL, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization...
-
May 30, 2013PDUFA Action Date Extended to February 28, 2014
SAN RAFAEL, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the...
-
May 20, 2013
SAN RAFAEL, Calif., May 20, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on May 15, 2013, the compensation committee of BioMarin's board of directors...
-
May 16, 2013Phase 3 Trial in gBRCA Breast Cancer Planned for 4Q 2013
SAN RAFAEL, Calif., May 16, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that data from its ongoing Phase 1/2 trial for BMN-673 for genetically-defined...
-
Apr 25, 2013Total Revenue Continues Steady Growth of 10 Percent; Progress on All Aspects of the Business
Financial Highlights ($ in millions, except per share data, unaudited) Q1 2013 Q1 2012 Percent Change Total BioMarin Revenue $ 127.9 $ 116.6 9.7% Total Net Product Revenue 127.3 116.2 9.6%...
-
Apr 24, 2013
SAN RAFAEL, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the European...
-
Apr 18, 2013
SAN RAFAEL, Calif., April 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on April 15, 2013, the compensation committee of BioMarin's board of...
-
Apr 1, 2013
SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...
-
Apr 1, 2013
SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has submitted a Clinical Trial Application (CTA) with the Medicines and...
-
Mar 25, 2013
SAN RAFAEL, Calif., March 25, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that an additional six holders of its 1.875% Convertible Senior Subordinated Notes...
-
Mar 19, 2013
NOVATO, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on March 15, 2013, the compensation committee of BioMarin's board of directors...
-
Mar 19, 2013BMN-701 Meaningfully Improves Respiratory Endpoints
SAN RAFAEL, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today results from POM-001, the Phase 1/2 trial for BMN-701, a fusion protein of...
-
Mar 18, 2013
SAN RAFAEL, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that seven holders of its 1.875% Convertible Senior Subordinated Notes due 2017...
-
Feb 21, 2013
SAN RAFAEL, Calif., Feb. 21, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has licensed a Factor VIII gene therapy program for hemophilia A from...
-
Feb 21, 2013Total Revenue in 2012 Exceeds $500 Million
Financial Highlights ($ in millions, except per share data, unaudited) FY 2012 FY 2011 Percent Change Total BioMarin Revenue $ 500.7 $ 441.4 13.4% Total Net Product Revenue 496.5 437.6 13.5%...
-
Feb 20, 2013
SAN RAFAEL, Calif., Feb. 20, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on February 15, 2013, the compensation committee of BioMarin's board of...
